Skylar Jeremias

Irritants, cleaning products, and mites tracked with SHE in 56,978 Dutch adults, although the exposure tool was built for occupational asthma.

Review finds 91 new lung cancer screening and pulmonary nodule AI tools, but few get external validation or calibration, risking flawed LDCT decisions.

A newly validated scoring instrument extends alopecia areata assessment to the eyebrows, eyelashes, and beard.

Selinexor, an oral XPO1 inhibitor, delivers modest spleen volume reduction in ruxolitinib-refractory MF with minimal myelosuppression in ESSENTIAL trial news.

This study links NT1 to anterior hypothalamus shrinkage, advancing orexin/hypocretin insights and a potential biomarker for narcolepsy with cataplexy.

A narrative review finds insomnia is a consistent, dose-dependent cardiovascular risk factor, but trials have not shown that treatment lowers risk.

A review maps psoriasis's 3-stage path to psoriatic arthritis and tools to catch it before joint damage.

Early secukinumab in new-onset psoriasis sustained PASI 90 in 1 of 5 patients a year after stopping treatment.

The AACR roadmap spotlights LDCT screening, ctDNA MRD monitoring, and new NSCLC/SCLC therapies like DLL3 tarlatamab to close survival gaps.

A Canadian expert panel says SALT scores miss the point: its new algorithm weighs quality of life and disease pace to guide alopecia areata treatment.

Chronic hand eczema affects roughly 5% of adults each year, exacts most of its toll at work, and is not simply atopic dermatitis of the hands.

Basement membrane composition actively drives NSCLC invasion, metastasis, and treatment resistance, a review finds, rather than serving as passive scaffolding.

Clinicians at a Chicago Population Health Roundtable say atopic dermatitis biologic therapy is delayed by several key obstacles.

At an AJMC roundtable, Atlanta clinicians detailed blood-based biomarker gaps, uncompensated care, and capacity strains slowing Alzheimer diagnosis.

An expert discusses gaps in pediatric alopecia areata evidence, missed trial outcomes, and what managed care should change for children with the disease.

Roundtable reveals vitiligo care gaps: Opzelura leads, insurers still call it cosmetic, and pricey oral JAKs near approval—what’s next?

Clinicians spotlight issues that stall pediatric atopic dermatitis escalation and biologic therapy access, despite worsening disease burden.

Although topical delgocitinib matched injectable dupilumab for CHE, real-world adherence could determine whether that holds outside clinical trials.

It also flagged persistent gaps in biomarker testing and the limits of cross-trial comparisons for treatment selection.

A narrative review links IL-17 signaling to metabolic syndrome and cardiovascular risk in psoriasis, though hard-outcome trial data remain limited.

Obesity may independently worsen psoriasis severity and blunt response to fixed-dose biologics, prompting calls for weight-adapted treatment selection.

A retrospective study of 76 patients at a Spanish allergy clinic found occupational exposure suspected in more than half of chronic hand eczema cases, with patch testing tying most sensitizations to preservatives, nickel, and rubber accelerants.

Brittany G. Craiglow, MD, FAAD, discusses JAK inhibitor hesitancy in pediatric alopecia areata, boxed warnings, and why step therapy falls short.

A review argues lung cancer screening should move beyond smoking history to include environmental exposures, family history, and AI-driven risk models, citing Taiwan's TALENT cohort as evidence broader eligibility finds cancer earlier.

Brittany G. Craiglow, MD, FAAD, discusses the psychiatric and psychosocial toll of alopecia in children and adolescents, and its impact on treatment initiation.

Paricalcitol shows more consistent parathyroid hormone control and a stronger survival signal than calcitriol in chronic kidney disease, though evidence for hard outcomes remains limited.

In the DELTA TEEN trial, 64% of adolescents with moderate to severe chronic hand eczema achieved clear or almost clear skin with delgocitinib cream versus 29% on vehicle, with mostly mild adverse events and no safety signals.

A budget impact model projects that covering delgocitinib cream for moderate to severe chronic hand eczema could save a hypothetical US health plan $87.8 million over 3 years, driven mostly by lower drug costs.

A new review argues that bulevirtide is unlikely to succeed as a stand-alone treatment and calls for combination regimens that restore antiviral immunity.

A dermatology review proposes sorting patients with overlapping atopic dermatitis and alopecia areata into 3 immunophenotype-guided archetypes to select and sequence systemic therapy.